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ABSTRACT
Physiotherapy management is a key element of care
for people with cystic ﬁbrosis (CF) throughout the
lifespan. Although considerable evidence exists to
support physiotherapy management of CF, there is
documented variation in practice. The aim of this
guideline is to optimize the physiotherapy manage-
ment of people with CF in Australia and New Zealand.
A systematic review of the literature in key areas of
physiotherapy practice for CF was undertaken. Rec-
ommendations were formulated based on National
Health and Medical Research Council (Australia)
guidelines and considered the quality, quantity and
level of the evidence; the consistency of the body of
evidence; the likely clinical impact; and applicability
to physiotherapy practice in Australia and New
Zealand. A total of 30 recommendations were made
for airway clearance therapy, inhalation therapy,
exercise assessment and training, musculoskeletal
management, management of urinary incontinence,
managing the newly diagnosed patient with CF, deliv-
ery of non-invasive ventilation, and physiotherapy
management before and after lung transplantation.
These recommendations can be used to underpin the
provision of evidence-based physiotherapy care to
people with CF in Australia and New Zealand.
Key words: airway clearance, cystic fibrosis, exercise, inhalation
therapy, physiotherapy.
Abbreviations: ACBT, active cycle of breathing technique; ACT,
airway clearance techniques; AD, Autogenic drainage; CF, cystic
fibrosis; CFRD, cystic fibrosis-related diabetes; FEV
1
, forced expira-
tory volume in 1 s; GOR, gastro-oesophageal reflux; PEP, Positive
expiratory pressure.
BACKGROUND
The aim of this Clinical Practice Guideline is to opti-
mize physiotherapy management of people with cys-
tic ﬁbrosis (CF) in Australia and New Zealand.
Recommendations for key areas of physiotherapy
management are provided, including airway clear-
ance therapy, inhalation therapy, exercise and
musculoskeletal management. This Clinical Practice
Guideline builds on a previous Consensus Statement
for physiotherapy management of CF in Australia1
and is informed by an evaluation of its uptake and
impact.2
*The extended version of the clinical practice guidelines pre-
sented in this paper can be found in the online supplementary
information. Any reference to the online supplementary infor-
mation should cite this Respirology paper as the primary
publication.
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METHODS
All physiotherapists who were regularly caring for
people with CF across paediatric and adult settings
in Australia and New Zealand were invited to partic-
ipate in guideline development. A systematic litera-
ture search was undertaken for each topic area up
until June 2014, using MEDLINE, CINAHL, EMBASE
and PEDro. Data from each included study were ex-
tracted into an evidence table by one reviewer and
checked by a second reviewer. Quality was graded
according to the NHMRC evidence hierarchy.3 Rec-
ommendations were formulated based on the qual-
ity, quantity and level of the evidence; the
consistency of the body of evidence; the likely clini-
cal impact; and generalizability and applicability to
physiotherapy practice in Australia and New
Zealand.3 Areas of importance to physiotherapy
practice, but with insufﬁcient evidence to make rec-
ommendations, were highlighted. Updates of each
section were prepared by a writing group and circu-
lated to all authors for comment and revision. The
draft document was offered to stakeholders for com-
ment, including CF physicians, CF consumers, allied
health professionals and physiotherapists who were
not part of the writing group.
This guideline provides recommendations for clini-
cal physiotherapy practice and a summary of the evi-
dence that underpins them. More details regarding
the evidence underpinning the recommendations
and application of the physiotherapy techniques can
be found in the Supplementary Appendix S1.
AIRWAY CLEARANCE TECHNIQUES
The aim of airway clearance techniques (ACT) is to
clear sputum from the airway, in order to optimize re-
spiratory status and slow disease progression. ACT are
frequently described as a ‘cornerstone’ of CF treat-
ment.4 A Cochrane review concluded that ACT have
short-term beneﬁcial effects on mucus transport in
CF.5 One uncontrolled study evaluated the effects of
withdrawing airway clearance for 3weeks and found
a detrimental effect on pulmonary function.6 Because
of ethical concerns regarding withholding such a
well-established treatment, it is considered unlikely
that more robust controlled trials of the long-term im-
pact of ACT in CF will be conducted.7
A number of effective ACT are available. The active
cycle of breathing technique (ACBT) consists of breath-
ing control, thoracic expansion exercises and forced
expirations.8 The ACBT is effective for clearance of re-
spiratory secretions9 with results comparable to other
widely used ACT.10 The ACBT can be performed by
all patients who can follow instructions and is useful
in all stages of disease. Positive expiratory pressure
(PEP) therapy is deﬁned as breathing against a PEP of
10–20cmH2O
11 using a mask or mouthpiece. A
Cochrane review concluded that PEP was equally
effective as other forms of ACT and that patients may
prefer PEP.12 Oscillating PEP combines oscillation of
airﬂow with PEP, in order to loosen secretions.13 In a
1-year randomised controlled trial (RCT) comparing
oscillating PEP with PEP in children with CF, greater
deterioration in pulmonary function and more
hospitalisations were seen in the oscillating PEP
group.14 However, amore recent 1-year study in adults
showed no difference in lung function between groups
randomly assigned to PEP or oscillating PEP.15 Auto-
genic drainage (AD) uses controlled breathing to
achieve the highest possible airﬂow in different gener-
ations of bronchi.16 Short-term studies have shown
that AD is as effective as postural drainage and percus-
sion,17 oscillating PEP18 and ACBT.19 In a long-term
comparative study in adolescents with CF, AD was as
effective as postural drainage, and participants showed
strong preference for AD.20 Several systematic reviews
note that no single ACT is superior,10,12,21 such that
treatment choices should be individualized.
Postural drainage involves use of gravity to drain
mucus from the lungs. A number of studies have dem-
onstrated provocation of gastro-oesophageal reﬂux
(GOR) during head-down tilted postural drainage in
infants, children and adolescents with CF.22–24 Two
additional studies did not reproduce these results in
infants, with no differences in GOR between modiﬁed
and traditional postural drainage25,26; however, the
head-down position utilized was not as steep, older
infants were studied and they avoided the prone
head-down tilted position.25 Other potential adverse
effects of postural drainage with head-down tilt in-
clude increased dyspnoea27 and oxyhaemoglobin
desaturation.28
Modiﬁed postural drainage involves positioning
without use of head-down tilt.22 In a 5-year follow-up
of infants randomized to either standard or modiﬁed
postural drainage, themodiﬁed group had fewer radio-
logical changes and signiﬁcantly better lung function at
6years of age.29 In a short-term adult study comparing
treatment in head-down versus horizontal positions,
there was no difference in the amount of sputum
expectorated, but patients reported fewer side effects
in horizontal positions.27
Physical exercise that increases minute ventilation
leads to the mobilization of pulmonary secretions and
enhances airway clearance.30–33 Some people with
mild CF lung disease use exercise together with forced
expiration and coughing as a stand-alone ACT. Others
with more extensive lung disease and larger volumes
of sputum use exercise as an adjunct to a formal ACT
regimen. Physiological effects of exercise include
reduced mechanical impedance of sputum, enhanced
expiratory ﬂow rates and inducement of coughing.34–38
A meta-analysis including three trials found that the
addition of exercise to ACT signiﬁcantly increased
forced expiratory volume in 1 s (FEV1) compared with
ACT alone.39 Whether exercise can be used as an
alternative to formal ACT is less clear, with conﬂicting
results across trials.31,32,38,40
1 ACT should be performed across the lifespan in
CF (C).
2 The ACBT is an effective form of airway clearance
and can be used by people with acute and chronic
lung disease independently or in conjunction with
other ACT (B).
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3 PEP therapy, oscillating PEP and AD are effective
forms of airway clearance, which can be performed
independently (B).
4 Postural drainage in head-down positions should
not be used routinely in infants with CF (B) or
in patients of any age with known or suspected
GOR (C). Modiﬁed postural drainage is recom-
mended in infants and young children where ac-
tive participation in airway clearance therapy is
not possible (B).
5 Physical exercise may be used to reduce mechanical
impedance of sputum (B), achieve short-term im-
provements in pulmonary function (A) and improve
ease of expectoration (B).
INHALATION THERAPY
Inhalation therapy is an important treatment for CF re-
spiratory disease. Effective inhalation therapy is inte-
gral to the success of ACT and vice versa; as a result,
physiotherapists should be adequately skilled in deliv-
ery of inhalation therapy in order to maximize the
effectiveness of both treatments.
The main determinants of deposition pattern for
nebulised medications are the breathing pattern dur-
ing inhalation, droplet size and age/condition of the
lung.41 A slower breath results in a more desirable pe-
ripheral deposition pattern, improved homogeneity
of deposition and increased overall drug deposition.42
Slow steady breaths with occasional deep breaths have
traditionally been recommended to promote im-
proved deposition.43 However, the speciﬁc device be-
ing utilized may determine the optimal breathing
pattern.44 Given the varying physico-chemical behav-
iours of the nebulised medications in CF, it is impor-
tant to use a nebuliser/compressor combination,
which is effective for the speciﬁc preparation.41
Nebulised medication should be taken via a mouth-
piece to maximize delivery of the drug to the airways
and avoid nasal ﬁltration.45 Exceptions are in young
children who may be unable to use a mouthpiece ef-
fectively, or where sinuses are a target of therapy, or
those with acute dyspnoea. Bronchodilators should
be delivered by metered dose inhaler and spacer41 ex-
cept where patients are too dyspnoeic or are unable
to follow instructions. Metered dose inhalers with
spacer should be used for administration of inhaled
corticosteroids. Patients should be encouraged to rinse
theirmouthwithwater and gargle afterwards to reduce
the risk of thrush.45
Combining ACT and inhalation therapy can reduce
the time-related burden of care in CF. However, stud-
ies have reported conﬂicting results of this practice
on lung deposition, bronchodilation, dyspnoea, cough
and mucus production.46–48 The combination of PEP
with inhalation therapy (hypertonic or isotonic saline,
salbutamol) is commonly used by physiotherapists.
Some also combine inhalation therapy with position-
ing and breathing techniques such as ACBT or AD.
There is insufﬁcient research investigating the combi-
nation of inhalation therapy and ACT to make recom-
mendations regarding this practice.
The optimal timing of inhalation of dornase alfa in
relation to ACT has been investigated in a Cochrane
systematic review.49Meta-analysis showed that inhala-
tion of dornase alfa after ACT had similar effects on
FEV1, forced vital capacity and quality of life compared
with inhalation prior to ACT. However, forced mid-
expiratory ﬂow25% was signiﬁcantly better with
dornase alfa inhalation before ACT, based on the
pooled data from two small studies in children with
well-preserved pulmonary function.50,51 A longer time
interval between administration of dornase alfa and
ACT ismore effective than inhalation immediately pre-
ceding ACT.52 There appears to be no detrimental ef-
fects on sleep quality or nocturnal cough if this time
interval is extended so that dornase alfa is adminis-
tered before bedtime.53 In the absence of strong evi-
dence to indicate that one regimen is better than
another, the timing of dornase alfa inhalation in rela-
tion to ACT or time of day can be based on pragmatic
reasons or individual preference.
The timing of hypertonic saline inhalation in relation
to ACT (before, during or after) does not appear to have
a substantial effect on lung function after a single treat-
ment session.54 However, participants were more sat-
isﬁed with the entire treatment session when
hypertonic saline was inhaled before or during ACT,
and perceived these timing regimens asmore effective.
6 Where possible, nebulised medication should be
taken via a mouthpiece (C).
7 To optimize dose delivery and treatment time, inha-
lation technique should be adapted to the device be-
ing used, including consideration of body position
and concurrent ACT (C).
8 Bronchodilators should be delivered by metered
dose inhaler unless there is clinical need for
nebulisation (C).
9 Metered dose inhalers with spacer should be used
for the administration of inhaled corticosteroids (B).
10 Hypertonic saline may be administered before or
during ACT (B).
EXERCISE ASSESSMENT AND TRAINING
Measures of exercise capacity predict survival in chil-
dren and adults with CF,55,56 and those with better
physical ﬁtness have better quality of life.57 Structured
exercise programmes for people with CF improve ﬁt-
ness and thoracicmobility,maintain bonemineral den-
sity and may slow the rate of pulmonary decline.58–64 A
study involving over 200 people with CF conducted
over 9years showed that patients with higher levels of
physical activity in daily life (encompassing all activities,
not just exercise programmes) had a slower rate of FEV1
decline than those who were less active.65
Exercise testing enables evaluation of exercise ca-
pacity, functional capacity, response to treatment and
disease progression.55,66–68 For physiotherapists, exer-
cise tests also provide the basis for exercise prescrip-
tion. Commonly used ﬁeld exercise tests in CF are the
6-min walk test, the modiﬁed shuttle walk test and
the 3-min step test. More details regarding the conduct
and choice of exercise test are provided in
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Supplementary Appendix S1. The 6-min walk test is
considered a particularly important measure during
preparation for lung transplantation in CF, providing
guidance regarding the timing of referral.69
Both aerobic training and anaerobic training are
beneﬁcial in CF.58 Aerobic training results in improved
maximum exercise capacity, strength and quality of
life.70,71 Anaerobic training has positive effects on lac-
tate levels, peak power72 and fat-freemass.71 Both types
of exercise may have positive effects on pulmonary
function.71,73 Exercise programmes have beneﬁcial ef-
fects both during admission for acute exacerba-
tions38,71,74 and for the stable outpatient.72,73,75 It is
unclear whether home-based, unsupervised training
programmes are equally as effective as supervised
programmes.
The ideal exercise prescription for people with CF
has not been established. In the absence of speciﬁc
guidelines, aerobic exercise prescription should follow
the same principles as those used in healthy individ-
uals76 and patients with other chronic respiratory dis-
eases.77 Exercise training should occur on at least
3days (preferably 5 ormore days) per week, have a du-
ration of 30min per session and increase heart rate to
75% of maximum heart rate. A combination of aerobic
and resistance training is required to achieve maxi-
mum beneﬁts.58
Patients with CF may exhibit exercise-induced oxy-
gen desaturation during training, even when pulmo-
nary function is well preserved.78 Supplemental
oxygen during training increases exercise duration79;
whether this improves clinical outcomes is not clear.
Supplemental oxygen is frequently used during train-
ing in patients whose oxygen saturation falls below
90% during exercise.80
11 Exercise is recommended for people with CF
throughout the lifespan (B).
12 An exercise test should be considered to assess
response to therapy in the inpatient and outpatient
settings and as an assessment tool in the prescrip-
tion of exercise training programmes (C).
13 A 6-min walk test should be performed as part of
the initial assessment for lung transplantation (C).
14 Exercise prescription should be tailored to the indi-
vidual and comply with recommended exercise
guidelines (B).
15 Supplemental oxygen should be considered during
training in patients with severe exercise-induced
desaturation (C).
MUSCULOSKELETAL COMPLICATIONS
OF CF
Musculoskeletal manifestations of CF arise as a result
of multifactorial abnormalities in bone mineraliza-
tion, altered respiratory mechanics and muscular
imbalance secondary to pulmonary disease. Between
43% and 94% of individuals with CF experience
spinal pain81–92, which occurs across the spectrum
of disease severity. Musculoskeletal pain in CF is
associated with decreased quality of life, increased
respiratory symptoms, sleep disturbance, anxiety,
depression and a reduced ability to perform ACT
and exercise.82,86,88–95
People with CF have multiple risk factors for inade-
quate bone mineralisation.96–100 Longitudinal studies
have shown that bone gains during puberty are de-
creased in CF adolescents compared with healthy con-
trols, resulting in decreased attainment of peak bone
mass.97,98,101–106 A meta-analysis reported that in CF,
the prevalence of osteoporosis and osteopenia was
23.5% and 38%, respectively.107 Individuals with more
severe lung disease, decreased physical activity and
low aerobic capacity had the lowest bonemineral den-
sity, higher prevalence of vertebral fractures and more
severe kyphosis.108
Weight-bearing exercise is the most effective
non-pharmacologicalmethod to improve bonemineral
density in the healthy population by stimulating bone
accretion, preventing bone loss and improving bone
structural qualities.106 As the foundation of bone health
begins in childhood and there is some evidence of
sustained beneﬁt from early vigorous physical activ-
ity,109,110 children and adolescents should engage in
high-impact weight-bearing exercise for 30min three
times a week. The prepubertal and early pubertal years
are particularly important to help maximize peak bone
mass101,111,112 as approximately one quarter of peak
bone mass is gained in the 2years around the pubertal
growth spurt.111,113
Changes in muscle strength, length and neuromus-
cular recruitment have been demonstrated in CF.
Reduced lean muscle mass is associated with malab-
sorption and deconditioning.114,115 Peripheral mus-
cle impairment is also noted in response to
systemic inﬂammation and lack of moderate to
vigorous physical activity.116,117 In CF, resistance
training programmes of moderate to high intensity
and variable duration (19days to 12months) have
produced signiﬁcant leg strength gains.118–120
Strength training for children is still a novel area with
protocols not clearly deﬁned; this is an area for future
research.120
Physiotherapists require the skills to manage a di-
verse range of musculoskeletal complications includ-
ing CF-related arthropathy, sports injuries, spinal
pain and pain associated with coughing. Early reports
regarding the use of manual therapy and exercise in
the management of pain and restriction are encourag-
ing.121,122 Patients with CF-related arthropathy require
rheumatological management, which may include
physiotherapy interventions targeting pain reduction
and muscle strengthening.
16 A musculoskeletal assessment should be included
at annual review from approximately age 8years
(prepuberty). Earlier assessment is warranted if
pain or functional impairment is reported or bone
mineral density risk highlighted (C).
17 Regular physical activity, including weight-bearing
exercise, should be encouraged throughout the
lifespan in order to optimize bone density (C).
18 Strength training programmes should be prescribed
in order to optimize muscle mass (B).
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PHYSIOTHERAPY MANAGEMENT OF THE
COMPLEX PATIENT
Cystic ﬁbrosis is a complex multisystem disease, and
patients often experience complications and comor-
bidities that have implications for physiotherapy man-
agement. These include haemoptysis, pneumothorax,
cystic ﬁbrosis-related diabetes (CFRD) and pregnancy.
There are no published data regarding physiothe-
rapy management of patients with haemoptysis or
pneumothorax; however, guidelines based on expert
opinion are available.123 When haemoptysis is present,
the physiotherapists aim to maintain adequate airway
clearance and exercise regimens whilst promoting ves-
sel healing and minimizing the risk of re-bleeding.
When a pneumothorax is present, physiotherapists
aim to ensure that adequate airway clearance con-
tinues whilst minimizing the amount of positive pres-
sure generated inside the patient’s lungs. Both of
these situations may require alteration to usual ACT.
Cystic ﬁbrosis-related diabetes is a frequent comor-
bidity in CF, occurring in 5–30% of patients. The Amer-
ican Diabetes Association Clinical Care Guidelines for
CFRD124 state that people with CFRD should perform
moderate aerobic exercise for at least 150min per
week, should monitor blood glucose levels before vig-
orous physical activity andmay need to consume extra
carbohydrate or alter their insulin dose (level of evi-
dence – expert opinion). During periods of acute illness
or courses of corticosteroids, blood sugar levels and in-
sulin requirements may be altered and more careful
monitoring required.124
Many pregnancy-related physiological changes
have implications for optimal physiotherapy care,
although little research is available. Women with CF
are encouraged to approach pregnancy with a regular
ACT routine. Head-down tilted postural drainage
should be avoided, along with any ACT that exacer-
bate nausea. Upright sitting is usually the most com-
fortable position for airway clearance. Modiﬁcations
to exercise programmes may be required to accom-
modate musculoskeletal, respiratory and cardiac
changes. Maintenance of adequate hydration during
exercise should be emphasized. It is important to
consider the need for domestic support during preg-
nancy and afterwards, to provide sufﬁcient time for
regular airway clearance, inhalation therapy and
exercise.125
PHYSIOTHERAPY MANAGEMENT OF
CONTINENCE
The reported prevalence of urinary incontinence in girls
and women with CF ranges from 22% to 74%126–132 in
comparison with 13% in healthy women of similar
age.133 There is limited literature in adult men with
CF, with a reported prevalence of 8–15%, compared
with 7.5% in healthy men.132,134,135 It is not known
whether the cause of urinary incontinence in CF is
chronic cough, loading of the pelvic ﬂoor during ACT,
coughing and physical exercise, or underlying structural
differences. People with CF and incontinence report
increased anxiety and depression and a negative impact
on quality of life.135,136
Screening for incontinence should be part of routine
physiotherapy care for both male and female patients.
Treatment of urinary incontinence in women with CF
by a continence physiotherapist with exercise, electri-
cal stimulation, biofeedback and bladder training
results in improvements in pelvicﬂoor strength, reduc-
tion in leakage and improvement in quality of life.137
Positive outcomes have also been demonstrated with
surgical correction of severe urinary incontinence in
women with CF.138 In order to optimize pelvic ﬂoor
function, patients should be taught to perform ACT in
positions thatmaintain a neutral lumbar spine,139 with
addition of perineal support in those with urinary
incontinence.
19 Womenwith CF and symptoms of stress urinary in-
continence should be taught rehabilitative strength
and endurance exercises to provide better control
of the pelvic ﬂoor (C).
20 Men and women with CF should be screened for
symptoms of stress urinary incontinence (C).
21 Airway clearance should take place in postures that
maintain a neutral lumbar spine, to optimize pelvic
ﬂoor function (C).
PHYSIOTHERAPY MANAGEMENT OF THE
NEWLY DIAGNOSED PATIENT
Newly diagnosed infants and their families shouldmeet
with the CF multidisciplinary team soon after diagno-
sis.140,141 The role of physiotherapy in ACT, exercise
and active play should be explained, demonstrated
and practised.142,143 Treatment of infants should follow
the usual guidelines for physiotherapy in CF, consisting
of ﬁve modiﬁed postural drainage positions performed
one to two times daily as appropriate.22,24,29 In each po-
sition, percussion or thoracic compressions should be
performed for 3–5min. Other techniques such as infant
PEP or assisted AD can also be introduced.144 Normal
developmental play and prone lying should be encour-
aged as the ﬁrst steps towards an active physical life-
style and routine.144,145
Adults and children with a new diagnosis of CF
usually have milder disease than those diagnosed in
infancy.142 Some newly diagnosed adults are very
well; therefore, physical exercise, hufﬁng and
coughing may be appropriate as stand-alone ACT.34
Those patients with established lung disease should
be taught appropriate ACT and exercise regimens
and educated about the role of nebulised drugs in
their treatment.
22 Treatment for newly diagnosed infantsmay include
percussion for 3–5min in each ofﬁvemodiﬁed pos-
tural drainage positions (B) and daily age-appropri-
ate physical play (C).
23 Physiotherapy treatment for the newly diagnosed
child and adult should include regular physical
exercise (B); other forms of airway clearance the-
rapy should be added as required (C).
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NON-INVASIVE VENTILATION FOR CF
A number of descriptive studies report the successful
use of non-invasive ventilation (NIV) to stabilize
patients with CF and acute respiratory failure,146–152
with reduced hypercapnia, respiratory rate and dys-
pnoea. Although NIV does not reverse the respiratory
deterioration inherent in end-stage disease, it may
allow the patient to be stabilized for long enough for
donor lungs to become available for transplantation.
The use of NIV for CF patients who are not awaiting
lung transplantation has also been reported151 where
it may be useful for palliation of dyspnoea in end-
stage disease.
Hypoxia and hypercapnia occur commonly during
sleep in moderate to severe CF153,154 and may result
in daytime respiratory failure.155 Positive short-term
effects of NIV during sleep in CF have been re-
ported.156,157 Longer-term outcomes of NIV for chronic
respiratory failure may include improvements in day-
time PaCO2, reduction in the number of days spent
in hospital and improvement in symptoms.158,159 In a
randomized controlled trial, domiciliary NIV over a
6-week period resulted in signiﬁcant improvements
in quality of life, respiratory symptom scores, dys-
pnoea, nocturnal ventilation and increased exercise
performance.160
Airway clearance techniques are onerous for pa-
tients who are unwell, because of increased ventilatory
demand,161 alterations in gas exchange28,162 and dys-
pnoea.27 Two randomized crossover trials report that
a single session of NIV can unload the respiratory
muscles during ACT in both adults and children with
CF, resulting in decreased dyspnoea and less
desaturation.162,163 Similar effects have been observed
with the application of NIV during exercise, including
improved ventilation, reduced desaturation and in-
creased functional walking performance.164 This may
be useful in patients bridging to transplantation, in
whom maintenance of exercise capacity is an impor-
tant goal.
Non-invasive ventilation delivers air at high ﬂow
rates and low relative humidity, whichmay overwhelm
the capacity of the upper airway mucosa to warm and
humidify inspired air.165 Humidity levels during NIV
are low enough to cause airway drying.166 This is of
greatest concern in patients with excessive secretions,
who are at high risk of sputum retention. Hence, con-
sideration should be given to heated humidiﬁcation
when NIV is used in CF.
24 NIV should be considered in all patients with acute
respiratory failure who are listed for transplanta-
tion (C).
25 In patients with symptomatic nocturnal ventilatory
failure, a trial of nocturnalNIVmaybeundertaken (B).
26 NIV is a useful adjunct to airway clearance in pa-
tients with severe disease in whom dyspnoea and
fatigue limit effective airway clearance (B).
27 NIV may be a useful adjunct to exercise in patients
with severe disease where dyspnoea and fatigue
contribute to deconditioning and limit effective
training (B).
28 Heated humidiﬁcation should be incorporated into
the circuit for all applications of NIV in CF (C).
PHYSIOTHERAPY AND LUNG
TRANSPLANTATION
There are many systemic features of CF that have the
potential to impact on lung transplant suitability and
outcomes, including skeletal muscle weakness167 and
poor bone health.63Most adult transplant centres offer
dedicated preoperative exercise training classes for
transplant candidates, in order to optimize physical ﬁt-
ness and strength. A recent large, retrospective study
that included 70 people with CF168 showed that 6-
min walk distance was well maintained from listing to
transplantation in those who undertook thrice-weekly
supervised exercise training. Furthermore, those with
a greater 6-min walk distance prior to transplantation
had a shorter hospital stay post-transplantation.
Exercise rehabilitation is an established therapy for
lung transplant recipients.169 Although studies in CF
are uncontrolled, 3months of post-transplant rehabil-
itation has been associated with improvements in
functional exercise capacity, strength and quality of life
in adults170 and children.171 A recent randomized con-
trolled trial of 3months of rehabilitation in lung trans-
plantation recipients with other respiratory disorders,
performed immediately following hospital discharge,
showed signiﬁcant improvements in daily physical ac-
tivity, quadriceps force and exercise performance at
1 year following transplantation.172 The content of
post-transplantation rehabilitation programmes gen-
erally includes aerobic and resistance exercise, per-
formed at least three times per week.169 Although
most rehabilitation takes place in a group setting, pa-
tients with resistant organisms may require isolation
from other immune-suppressed patients.
29 Patients with CF should undertake an exercise pro-
gramme designed to optimize their physical func-
tion whilst on the transplant waiting list (C).
30 Patients with CF who have undergone lung trans-
plantation should participate in a formal, supervised
rehabilitation programme post-operatively (B).
END OF LIFE CARE
There is no published literature speciﬁcally addressing
physiotherapy treatment in the terminal stages of CF.
However, many people with CF die of respiratory fail-
ure,173 and physiotherapists are often involved with
provision of end of life care. The aims of physiotherapy
treatment will be inﬂuenced by whether the patient is
actively waiting for transplantation. Care should focus
on comfort and dignity and be tailored to each pa-
tient’s goals and values.174 Minimizing the work of
breathing during ACT is an important consideration
in those approaching the end of life. Some patients
may require therapist-assisted ACT such as percussion
or thoracic compressions. Airway clearance may be
continued even in the palliative stage if the patient
ﬁnds it beneﬁcial to relieve symptoms. Comfort
Physiotherapy guidelines for cystic fibrosis 661
© 2016 The Authors
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology
Respirology (2016) 21, 656–667
measures such as soft tissue massage and positioning
can also be considered.
INFECTION CONTROL
Respiratory pathogens have a signiﬁcant impact on
morbidity and mortality in CF,175 and good infection
control practices are critical to preventing their
transmission. Segregation and cohorting of inpa-
tients and outpatients according to respiratory or-
ganisms are now routinely practised.176,177
Physiotherapists are encouraged to be familiar with
their local infection control policies. Because of con-
siderable variation in local policies, formal recom-
mendations are not provided here.
Both Pseudomonas aeruginosa and Burkholderia
cepacia may be spread in droplet form by coughing
and can survive on dry surfaces for a number of
days.178–180 There is also potential for airborne trans-
mission.181 B. cepacia has been isolated from the
hospital rooms and hands of patients following air-
way clearance182–184 and the outside surfaces of spu-
tum cups.182 These ﬁndings reinforce the need to
segregate patients whilst performing ACT and inhala-
tion therapy, as well as the importance of hand
washing. Stethoscopes should be cleaned with alco-
hol wipes between patients.185
Bacterial contamination of home nebulisers has
been documented, and sharing equipment has been
associated with transmission of B. cepacia.186–188 Un-
der no circumstances should any respiratory equip-
ment be shared between patients with CF. There is
no consensus regarding the use of gloves, gowns and
masks during physiotherapy treatment in CF. Physio-
therapists should consult their local infection control
policy with regard to when these measures are
required.
Coughing is common during exercise, and droplet
spread of organisms is possible. These droplets may
be transmitted within 1m of an infected patient.178 It
has been reported that contamination can still occur
between 1 and 2m, albeit with lower probability
(1.7%).189 As a result, patients with different organisms,
or in different cohorts, do not exercise together. When
people considered suitable for cohorting are sharing
the gym, universal precautions should be practised.
Patients should be educated to maintain a 2-m dis-
tance from other patients at all times, hands should
be washed on entering and leaving the gym and pa-
tients should be taught to wipe down all exercise
equipment with an alcohol-based solution before and
after use.
PHYSIOTHERAPY SERVICES FOR CF
There is no published research regarding the optimum
structure of physiotherapy services for people with CF.
For inpatients, expert clinical opinion suggests that
physiotherapy assessment and treatment starts on
the day of hospital admission.190 The physiotherapy
treatment plan should address inhalation therapy,
ACT and exercise. Patients admitted with an acute
exacerbation with increased and/or retained secre-
tions will need to carry outmore frequent ACT sessions
than their baseline daily regimen. The number of treat-
ments will range from two to three or more treatments
in 24h. A graduated physical exercise programme in-
corporating cardiorespiratory exercise should be com-
menced as soon as possible.
Patients attending the outpatient department of a
Cystic Fibrosis Service should have access to a physio-
therapist with expertise in CF management at each
clinic visit. It is suggested that each patient be assessed
three to six monthly so that their physiotherapy
programme can be reviewed and optimized. Complex
patients may require more frequent and detailed re-
view. A formal annual review by the CF team, including
physiotherapy review, has been advocated for people
with CF.190,191
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